Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Indwelling Device-associated Biofilms (BiofilmICU)

14 de marzo de 2022 actualizado por: Olguta Lungu, Grigore T. Popa University of Medicine and Pharmacy

Indwelling Device-associated Biofilms in Oncological Critically Ill Patients

Healthcare associated infections linked to the use of indwelling medical devices increase hospital morbidity, mortality and the Intensive Care treatment costs. The essential strategy for mitigating these consequences are prompt source identifcation and control, with appropriate antimicrobial therapy initiation as soon as possible. Removing the source is one of the golden rule for infection control. Early identification of the responsible germs is the other major guiding element for the appropriate anti-infectious treatment.

Despite multiple detection/identification methods, there are no clear recommendations for biofilm identification in clinical practice. The gold standard method is bacterial/fungal culturing, with disadvantages related to late results, especially for slow growing, fastidious germs or related to the existence of uncultivable strains.

In order to obtain more sensitive, specific results and to increase the chances of better biofilm characterization, in the present study the investigators compare biofilm identification results obtained by standard cultivation methods with those by DNA amplification and next generation gene sequencing. The studied biofilm is associated to four criticallly ill oncological patients indwelling devices (endotracheal tube, central venous catheter, arterial catheter and urinary catheter).

Descripción general del estudio

Descripción detallada

According to Regional Institute of Oncology, Iasi protocols, all septic patients with the need of invasive ventilatory support (endotracheal intubation), have concomitantly inserted a CVC, an AC and a UC, as standard of care. All patients undergo the protocol for the management of suspected/proven sepsis: initial resuscitation, specimen collection for microbiology/molecular biology tests, empirical/targeted anti-infectious treatment, source control, multiple organ support and treatment of the underlying disease/comorbidities. All RIO patients are screened for nasal, pharyngeal and rectal pathogen colonization at the time of hospital/ICU admission.

Informed consent - During the first 24 hours of ICU admission, all eligible patients will receive written information about the study: its implementation, aims, expected advantages and possible risks, and they will be asked to sign an informed consent. If the patient is unable to give consent at ICU admission due to pathological or drug-induced acute alteration of consciousness, a legal representative may give authorization. Once the participant regains the decision capacity, the individual will be asked to confirm or withdraw consent.

Swab sampling - The nasal, pharyngeal and rectal screening swab sampling is collected according to standard methods. In addition to this standard screening, in the first 24 hours of ICU admission cutaneous samples from the groin area of enrolled patients will be obtained, with sterile Copan eSwabTM swabs, a product recommended for aerobic, anaerobic and fastidious microbial agents.

Biofilm sampling and transport - The extraction of the four ID (ET, CVC, AC, UC) will be performed when the clinical condition of the patient dictates it (suspected catheter infection/no further need due to improvement or death). These devices will be extracted by medical ICU personnel, only at the indication and according to the medical judgment of the clinician, without being influenced by the patient's study participation.

Microbiological processing and analysis of the biofilm - Microbiological analysis will be performed by standard method: sample seeding on standard culture media, then biochemical identification test and AST according to CLSI standards and guidelines using MicroScan Walk Away 40 plus®, Beckmann Coulter automatic system compatible pannels.

Molecular biology processing and analysis of the biofilm - After complete sample collection, gene sequencing of the variable regions V3-V4 16S rRNA gene will be performed using Illumina MiSeq® Next Generation Sequencer System.

Tipo de estudio

De observación

Inscripción (Anticipado)

150

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Iasi, Rumania, 7--483
        • Regional Institute of Oncology

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

All consecutive critical oncology patients, which meet all inclusion criteria and have no exclusion criteria, admitted to the Intensive Care clinic of the Regional Oncology Institute, Iasi, Romania.

Descripción

Inclusion criteria:

  1. Signed informed consent;
  2. Age ≥18 years;
  3. Suspected/proven sepsis/septic shock (Supplemental file 2);
  4. APACHE II score ≥10 (Supplemental file 3);
  5. Predictable invasive ventilatory support ≥ 48 hours;
  6. Patient estimated survival ≥ 4 days.

Exclusion criteria:

  1. Patient/legal representative refusal;
  2. Age <18 years;
  3. Chronic psychiatric/neurological disease with impaired decision-making capacity;
  4. Pregnancy;
  5. Invasive ventilatory support < 2 days;
  6. Death in less than 4 days after ICU admission.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The detection/identification of biofilm-associated pathogens
Periodo de tiempo: through study completion, an average of 1 year
The detection/identification of biofilm-associated pathogens using Next Generation Sequencing (NGS) technique compared with standard microbiological diagnosis.
through study completion, an average of 1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Identification of pathogens involved in ID biofilm formation
Periodo de tiempo: through study completion, an average of 1 year
Identification of pathogens involved in ID biofilm formation (ET, CVC, AC, UC) in the critically ill oncological patients.
through study completion, an average of 1 year
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples
Periodo de tiempo: through study completion, an average of 1 year
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
through study completion, an average of 1 year
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
Periodo de tiempo: through study completion, an average of 1 year
Comparison of the biofilm-associated pathogens with those identified in currently used biological samples (tracheal aspirate/bronchoalveolar lavage, blood culture, urinary culture, surgical wound swab, etc.) collected from the same patient.
through study completion, an average of 1 year
Establishing clinico-biological correlations
Periodo de tiempo: through study completion, an average of 1 year

Correlations between biofilm-associated pathogens and patient clinico-biological data:

  • nasal, pharyngeal, rectal and skin pathogen screening;
  • associated risk factors: neutropenia, chemo/radiotherapy, corticosteroid treatment, previous anti-infectious therapy;
  • ID exposure time;
  • biological markers of inflammation;
  • diagnosed infection: respiratory tract infection, urinary tract infection, bloodstream infection, surgical site infection, sepsis of unknown origin, etc.;
  • severity scores: Sequential [Sepsis-Related] Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score;
  • ICU and hospital LOS;
  • patient's outcome: survival/death;
through study completion, an average of 1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Luminita Smaranda Iancu, Professor, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
  • Director de estudio: Ioana Grigoras, Professor, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
  • Director de estudio: Olivia Simona Dorneanu, Assoc Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
  • Director de estudio: Catalina Lunca, Assist Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
  • Silla de estudio: Teodora Vremera, Assist Prof, University of Medicine and Pharmacy "Grigore T Popa", Iasi, Romania
  • Silla de estudio: Stefania Brandusa Copacianu, MD, PhD, Regional Institute of Oncology Iasi, Romania
  • Silla de estudio: Iuliu Ivanov, PhD, Regional Institute of Oncology Iasi, Romania

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de junio de 2019

Finalización primaria (Anticipado)

5 de septiembre de 2023

Finalización del estudio (Anticipado)

5 de octubre de 2025

Fechas de registro del estudio

Enviado por primera vez

27 de marzo de 2020

Primero enviado que cumplió con los criterios de control de calidad

30 de marzo de 2020

Publicado por primera vez (Actual)

31 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de marzo de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

14 de marzo de 2022

Última verificación

1 de marzo de 2022

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • GTPopaUMPIASI

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Descripción del plan IPD

Patient report form, patient microbiological study sheet, patient device study sheet.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Septicemia

3
Suscribir